1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Clinical data of patients with residual plaque ulceration
Men25 (83%)
29 lesions (85%)
Women5 (17%)
5 lesions (15%)
Age (y)
    Mean ± SD71 ± 7.3
    Range50–81
Side
    Right17
    Left17
Symptomatic lesion27 (79%)
Size of ulcer (mm; mean ± SD)
    Depth2.1 ± 0.8
    Length8.9 ± 4.4
Follow-up angiography (n = 25)
    Period (mo, mean ± SD)5.8 ± 4.3
    Ulcer
        Disappeared12 (48%)
        Improved11 (44%)
        No change2 (8%)
    Restenosis
        30%2 (8%)
        20%7 (28%)
        None16 (64%)
Follow-up period (mo)
    Mean ± SD25.5 ± 10.4
    Range3–48
Symptoms* during follow-up0 (0%)
  • * Ipsilateral ischemic neurologic symptoms.